Narcolepsy Treatments Are Advancing. Can Access?
Race, age, and other factors are linked to disparities in care for people with narcolepsy.
Category: Pharmaceuticals
Pharmaceuticals
Latest
Pharmaceuticals
Latest
Apnimed Appoints New CEO as Investigational OSA Therapy Nears FDA Decision
The late-stage pharmaceutical company announces a leadership transition as it prepares for the potential commercialization of its once-daily oral therapy for obstructive sleep apnea.
Pharmaceuticals
Latest
Phase 3 Data Published for Once-Nightly OSA Drug Candidate AD109
Results from the SynAIRgy trial show the investigational oral therapy AD109 significantly reduced airway obstruction and improved oxygenation in patients with obstructive sleep apnea.
Prescription Drugs
Latest
Drug Shows Promise for Reducing Excessive Sleepiness in Early Morning Shift Workers
A new clinical trial from Mass General Brigham found that a drug approved for other indications helped early morning shift workers with shift work disorder stay more alert.
Over-the-Counter Treatments
Latest
Saline Nasal Spray Shows Efficacy in Treating Pediatric Sleep-Disordered Breathing
A new Australian study finds that a simple saline nasal spray can resolve symptoms of obstructive sleep-disordered breathing in children, potentially reducing the need for surgery and specialist care.
Emerging Compounds
Latest
Alkermes Starts Phase 3 Program for Narcolepsy Drug Candidate Alixorexton
It will analyze once-daily and split-dose regimens of the oral orexin 2 receptor agonist in people with narcolepsy type 1 and type 2.